Psoriasis Completed Phase 2 Trials for Bermekimab (DB14947)

Also known as: Psoriasis unspecified / Psoriasis, unspecified

IndicationStatusPhase
DBCOND0013339 (Psoriasis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01384630Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe PsoriasisTreatment